Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Ebola Virus Vaccine Market size was over USD 7.5 billion in 2024 and is projected to reach USD 296.74 billion by 2037, growing at around 32.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of ebola virus vaccine is assessed at USD 9.58 billion.
The Ministry of Health in Democratic Republic of the Congo reported that as of March 10, 2020, there have been a total of 3,444 cases, out of which 3,310 are confirmed and 134 are probable. This number includes 2,264 deaths, 1,169 survivors as well as the patients that are still under care. This has been labelled as the world’s second largest Ebola epidemic and was declared on August 1, 2018.
Ebola Virus Vaccine Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Ebola Virus Disease to Drive the Demand for Ebola Virus Vaccine: According to the Centers for Disease Control and Prevention, the Democratic Republic of the Congo (DRC) experienced its tenth Ebola virus disease outbreak in 2019, during which a total of 3,296 cases of Ebola were reported as on November 17, 2019. Along with this, 2,196 deaths were reported as well. The World Health Organization termed this Ebola virus disease outbreak as a public health emergency of international concern on July 17, 2019.
The growing number of deaths as a result of Ebola virus disease and the need for effective treatment methods in the affected regions is anticipated to become a major growth driving factor for the market. - Increasing R&D by Companies to Boost the Market Growth: The measures being taken by various pharmaceutical companies and governments all across the world for the development of drugs and vaccines for the treatment of Ebola virus disease is another important factor estimated to result in the market growth in near future.
Challenges
- Strict Government Regulations for Drug Approvals to Hinder the Market Growth: Despite the increasing research and development activities for ebola virus vaccine development by various leading companies and the growing demand for such vaccines, the strict rules and regulations for approval of these vaccines is estimated to restrict the market growth.
Ebola Virus Vaccine Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
32.7% |
|
Base Year Market Size (2023) |
USD 5.65 billion |
|
Forecast Year Market Size (2036) |
USD 223.55 billion |
|
Regional Scope |
|
Ebola Virus Vaccine Segmentation
There are four types of Ebola virus strains that are known to affect humans. These consist of: Ebola virus (Zaire ebolavirus), Sudan virus (Sudan ebolavirus), Taï Forest virus (Taï Forest ebolavirus) and Bundibugyo virus (Bundibugyo ebolavirus). The market is segmented by virus type, by end user and by region. On the basis of virus type, the market is segmented into Ebola virus, Sudan virus, Taï Forest virus and Bundibugyo virus, out of which, the segment for Ebola virus is anticipated to hold the largest share in the ebola virus vaccine market. The growth of this segment can be attributed to the high occurrence of Ebola virus among people as compared with the other strains of the virus.
Our in-depth analysis of the global market includes the following segments
|
By Virus Type |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportEbola Virus Vaccine Industry - Regional Synopsis
On the basis of regional analysis, the ebola virus vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is anticipated to hold largest revenue share by 2037, as research and development for Ebola virus disease treatment is rapidly progressing in the region. Moreover, the market in this region is anticipated to grow at the highest rate during the forecast period as a result of growing development of vaccines and drugs in the healthcare industry along with the presence of leading pharmaceutical companies in North America. Additionally, ebola virus vaccine market in Asia Pacific region is estimated to observe substantial growth on the back of rising funding by the governments, mainly in countries such as China and India. On the other hand, the Middle East and Africa region is anticipated to witness the highest demand for ebola virus vaccines as the disease is majorly prevalent in the African region.
Companies Dominating the Ebola Virus Vaccine Landscape
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sarepta Therapeutics
- Mapp Biopharmaceutical
- Regeneron Pharmaceuticals, Inc.
- GlaxoSmithKline plc.
- Novavax, Inc.
- GeoVax
- Tekmira Pharmaceuticals
- NewLink Genetics Corporation
- Bavarian Nordic
In the News
Author Credits: Radhika Pawar
- Report ID: 2348
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
